keyword
MENU ▼
Read by QxMD icon Read
search

multiple sclerosys

keyword
https://www.readbyqxmd.com/read/28644283/new-drug-for-multiple-sclerosis
#1
Diane S Aschenbrenner
No abstract text is available yet for this article.
July 2017: American Journal of Nursing
https://www.readbyqxmd.com/read/28644112/susac-syndrome-misdiagnosed-as-multiple-sclerosis-with-exacerbation-by-interferon-beta-therapy
#2
Hussein Algahtani, Bader Shirah, Muhammad Amin, Eyad Altarazi, Hashem Almarzouki
Susac syndrome is a rare autoimmune disorder characterised by the clinical triad of encephalopathy, retinopathy (branch retinal artery occlusions) and hearing loss. The diagnosis of Susac syndrome may be difficult initially, and it is not uncommon for patients with Susac syndrome to be misdiagnosed with multiple sclerosis. In this case report, we describe a patient who was diagnosed as having multiple sclerosis for three years, with further deterioration after starting treatment with interferon beta-1a. The patient had the triad of encephalopathy, branch retinal artery occlusions and sensorineural hearing loss...
January 1, 2017: Neuroradiology Journal
https://www.readbyqxmd.com/read/28643955/diffusion-tensor-imaging-of-normal-appearing-white-matter-in-patients-with-neuromyelitis-optica-spectrum-disorder-and-multiple-sclerosis
#3
S-H Kim, K Kwak, J-W Hyun, A Joung, S H Lee, Y-H Choi, J-M Lee, H J Kim
BACKGROUND AND PURPOSE: The occult changes in normal-appearing white matter (NAWM) were investigated and compared amongst patients with neuromyelitis optica spectrum disorder (NMOSD), patients with multiple sclerosis (MS) and healthy controls (HCs) by applying tract-based spatial statistics to diffusion tensor imaging (DTI) data. METHODS: Diffusion tensor imaging was performed with a 3-T scanner in 93 patients with NMOSD, 53 patients with MS and 43 HCs. Voxel-wise statistical analyses of the DTI data were performed using tract-based spatial statistics...
July 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28643601/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-sweden
#4
Lou Brundin, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
BACKGROUND: To assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in 2015 SEK...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643600/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-italy
#5
Mario Battaglia, Gisela Kobelt, Michela Ponzio, Jenny Berg, Daniela Capsa, Johan Dalén
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643599/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-austria
#6
Thomas Berger, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643598/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-belgium
#7
Benedicte Dubois, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643597/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-spain
#8
Celia Oreja-Guevara, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) where lifetime costs and outcomes cannot be observed, outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643596/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-switzerland
#9
Pasquale Calabrese, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643595/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-the-netherlands
#10
Bernard Uitdehaag, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643593/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-germany
#11
Peter Flachenecker, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643592/the-burden-of-multiple-sclerosis-2015-methods-of-data-collection-assessment-and-analysis-of-costs-quality-of-life-and-symptoms
#12
Gisela Kobelt, Jennifer Eriksson, Glenn Phillips, Jenny Berg
INTRODUCTION: This article describes the methods used to perform this large European-wide burden-of-illness study on multiple sclerosis (MS) using individual patient data. METHODS: The study collected all MS-related resource consumption, workforce participation, prevalent disease symptoms and health-related quality of life (HRQoL). Patients were recruited by national patient associations and, after informed consent, completed a specific questionnaire either on-line or on paper...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643591/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-hungary
#13
Márta Péntek, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén, Zita Bíró, Klotild Mátyás, Sámuel Komoly
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643590/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-russia
#14
Alexey Boyko, Gisela Kobelt, Jenny Berg, Olga Boyko, Ekaterina Popova, Daniela Capsa, Jennifer Eriksson
BACKGROUND: In order to assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in RUB 2015...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643589/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-denmark
#15
Peter Vestergaard Rasmussen, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
BACKGROUND: To estimate the value of treatments in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643588/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-france
#16
Christine Lebrun-Frenay, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl
INTRODUCTION: To estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643587/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-the-united-kingdom
#17
Alan Thompson, Gisela Kobelt, Jenny Berg, Daniela Capsa, Jennifer Eriksson, David Miller
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643586/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-poland
#18
Krzysztof Selmaj, Gisela Kobelt, Jenny Berg, Ewa Orlewska, Daniela Capsa, Johan Dalén
BACKGROUND: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 European countries collecting current data on resource consumption, work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643585/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-for-portugal
#19
Maria José Sá, Gisela Kobelt, Jenny Berg, Daniela Capsa, Johan Dalén
BACKGROUND: In order to assess the value of management strategies in multiple sclerosis (MS), outcome data have to be combined with cost data. This, in turn, requires that cost data be regularly updated. OBJECTIVE AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting current data on resource consumption, work capacity and health-related quality of life (HRQoL). Descriptive analyses are presented by level of severity; costs are estimated in the societal perspective, in EUR 2015...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28643584/new-insights-into-the-burden-and-costs-of-multiple-sclerosis-in-europe-results-of-the-czech-republic
#20
Eva Havrdova, Gisela Kobelt, Jenny Berg, Daniela Capsa, Mia Gannedahl, Tomáš Doležal
INTRODUCTION: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. OBJECTIVES AND METHODS: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS...
August 2017: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
75562
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"